Rash from EGFR inhibitors: Opportunities and challenges for palliation

  • B.M. S
  • A. J
ISSN: 1523-3790
N/ACitations
Citations of this article
3Readers
Mendeley users who have this article in their library.

Abstract

The epidermal growth factor receptor (EGFR) inhibitors represent a relatively new class of cancer agents that also provide new challenging side effects for cancer patients. This article reviews the clinical aspects of EGFR inhibitor-induced rash, which occurs most commonly with use of these agents, and discusses some of the challenges faced in attempting palliation treatment. (copyright) Current Medicine Group LLC 2008.

Cite

CITATION STYLE

APA

B.M., S., & A., J. (2008). Rash from EGFR inhibitors: Opportunities and challenges for palliation. Current Oncology Reports, 10(4), 304–308. Retrieved from http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L354099624

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free